Search Results

You are looking at 11 - 20 of 131 items for :

  • "symptom burden" x
  • Refine by Access: All x
Clear All
Full access

Screening Tool Identifies Older Adults With Cancer at Risk for Poor Outcomes

Ryan D. Nipp, Leah L. Thompson, Brandon Temel, Charn-Xin Fuh, Christine Server, Paul S. Kay, Sophia Landay, Daniel E. Lage, Lara Traeger, Erin Scott, Vicki A. Jackson, Nora K. Horick, Joseph A. Greer, Areej El-Jawahri, and Jennifer S. Temel

adults with cancer who may experience poor outcomes. Although older patients with cancer represent an increasing and heterogeneous population with diverse needs, little research has sought to identify those at risk of experiencing high symptom burden or

Full access

Psychological Symptoms Among Patients With BCR-ABL–Negative Myeloproliferative Neoplasms

Daniel C. McFarland, Heather Polizzi, John Mascarenhas, Marina Kremyanskaya, Jimmie Holland, and Ronald Hoffman

Background The prevalence of distress, anxiety, and depressive symptoms has not been assessed by standard measures in patients with BCR-ABL–negative myeloproliferative neoplasms (MPNs). This is perhaps surprising given the large symptom burden

Full access

Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life

Jamie M. Jacobs, Molly E. Ream, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Joanne Buzaglo, Inga T. Lennes, Steven A. Safren, William F. Pirl, Jennifer S. Temel, and Joseph A. Greer

those on intravenous treatment, 10 , 11 which could negatively influence adherence, 12 it is important to understand patients’ symptom burden, adherence, and distress in a clinical setting. Although oral therapy is thought to impair QoL less than

Full access

Prevalence of Physical Problems Detected by the Distress Thermometer and Problem List in Patients With Myeloproliferative Disorders

Daniel C. McFarland, Kelly M. Shaffer, Heather Polizzi, John Mascarenhas, Marina Kremyanskaya, Jimmie Holland, and Ronald Hoffman

Myeloproliferative neoplasms (MPNs) are a unique form of hematologic malignancy that are characterized by an elevated rate of physical symptom burden along a progressive and chronic disease trajectory. 1 Patients with MPNs often report high

Full access

Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms

Brady L. Stein, Jason Gotlib, Murat Arcasoy, Marie Huong Nguyen, Neil Shah, Alison Moliterno, Catriona Jamieson, Daniel A. Pollyea, Bart Scott, Martha Wadleigh, Ross Levine, Rami Komrokji, Rebecca Klisovic, Krishna Gundabolu, Patricia Kropf, Meir Wetzler, Stephen T. Oh, Raul Ribeiro, Rita Paschal, Sanjay Mohan, Nikolai Podoltsev, Josef Prchal, Moshe Talpaz, David Snyder, Srdan Verstovsek, and Ruben A. Mesa

addition, more clarity now exists regarding the impact of the MPN symptom burden, attributed partly to cytokine excess, splenomegaly, hyperviscosity (PV), thrombotic complications, and cytopenias (MF). In some patients with MF, the impairment in quality of

Full access

Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?

Kamya Sankar and Brady L. Stein

provided molecular targets for drug development in both PV and ET. The primary goals of treatment for MPNs are to reduce the risk of thrombosis and alleviate systemic symptom burden (eg, fatigue, pruritus, microvascular symptoms, symptomatic splenomegaly

Full access

Pilot Randomized Trial of a Transdisciplinary Geriatric and Palliative Care Intervention for Older Adults With Cancer

Ryan D. Nipp, Brandon Temel, Charn-Xin Fuh, Paul Kay, Sophia Landay, Daniel Lage, Esteban Franco-Garcia, Erin Scott, Erin Stevens, Terrence O’Malley, Supriya Mohile, William Dale, Lara Traeger, Ardeshir Z. Hashmi, Vicki Jackson, Joseph A. Greer, Areej El-Jawahri, and Jennifer S. Temel

add to the complexity of caring for older adults with cancer. Older patients experience unique concerns related to their physical function, comorbid conditions, and medication management (ie, geriatric-specific issues), as well as their symptom burden

Full access

Outcomes From a Patient-Centered, Interprofessional, Palliative Consult Team in Oncology

Andrea Feldstain, Barry D. Bultz, Janet de Groot, Amane Abdul-Razzak, Leonie Herx, Lyle Galloway, Srini Chary, and Aynharan Sinnarajah

. Integration in these ways is of particular importance in CCMS patient populations who demonstrate a “complex” symptom burden, often influenced by a number of biopsychosocial concerns. 6 – 8 It allows for better coordinated interprofessional approaches and

Full access

A Prospective Cohort Study of Stability in Preferred Place of Death Among Patients With Stage IV Cancer in Singapore

Chetna Malhotra, Ling En Koh, Irene Teo, Semra Ozdemir, Isha Chaudhry, and Eric Finkelstein

and previous literature on EoL preferences, 15 – 19 we hypothesized that preferred PoD and the stability of that preference will be associated with time-varying factors, including patients’ psychologic distress, symptom burden, quality of life (QoL

Full access

HSR19-100: CancerSupportSource®-15: Development and Evaluation of a Short Form of a Distress Screening Program for Cancer Survivors

Shauna McManus, Alexandra K. Zaleta, Melissa F. Miller, Joanne S. Buzaglo, Julie S. Olson, Sara Goldberger, and Kevin Stein

anxiety risk screening subscales), (2) symptom burden, (3) body and healthy lifestyle, (4) healthcare team communication, and (5) relationships. This study developed a short form of CSS and examined its psychometric properties. Methods: 2,379 cancer